ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 117 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,107 | -49.3% | 9,248 | -9.1% | 0.03% | -47.4% |
| Q2 2023 | $96,939 | +44.8% | 10,172 | +67.1% | 0.06% | +54.1% |
| Q1 2023 | $66,968 | -46.3% | 6,088 | -27.7% | 0.04% | -43.1% |
| Q4 2022 | $124,660 | +23.4% | 8,423 | +59.7% | 0.06% | +62.5% |
| Q3 2022 | $101,000 | -9.0% | 5,275 | +0.8% | 0.04% | -2.4% |
| Q2 2022 | $111,000 | -44.5% | 5,232 | -49.5% | 0.04% | -54.4% |
| Q1 2022 | $200,000 | -11.9% | 10,359 | -5.5% | 0.09% | +4.7% |
| Q4 2021 | $227,000 | +30.5% | 10,965 | +50.1% | 0.09% | +11.7% |
| Q3 2021 | $174,000 | -17.1% | 7,304 | -5.0% | 0.08% | -10.5% |
| Q2 2021 | $210,000 | -29.5% | 7,692 | -25.3% | 0.09% | -31.7% |
| Q1 2021 | $298,000 | +4.6% | 10,302 | +1.8% | 0.13% | +6.8% |
| Q4 2020 | $285,000 | -19.5% | 10,117 | -16.3% | 0.12% | -36.6% |
| Q3 2020 | $354,000 | -14.7% | 12,081 | -11.9% | 0.19% | -5.6% |
| Q2 2020 | $415,000 | – | 13,718 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |